Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer

Inclusion Criteria: * Living in India for the duration of the study * Adult females over age 18 years of age with a life expectancy of at least 3 months * Confirmed breast cancer with evidence of locally advanced or metastatic disease * Disease that is measurable by radiology imaging * Ambulatory and capable of all selfcare but unable to carry out any work activities. * Adequate laboratory results (hematologic, renal, hepatic) * Negative pregnancy test Exclusion Criteria: * History of or susceptibility to bleeding or coagulopathy (e.g., von Willebrand Disease or Hemophilia) * Any history of thromboembolic events (clots within blood vessels) * Ongoing treatment with high doses of anticoagulants * Use of hormone therapy * Advanced peripheral neuropathy (e.g., numbness, tingling, and/or pain in distal extremities) * Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease unless disease had recurred after radiotherapy * Radiotherapy within 2 weeks entering the study * Chemotherapy, immunotherapy or radiotherapy within 4 weeks of starting the study * Allergies to Polysorbate 80 or drugs containing polyoxyethylated castor oil (e.g. cyclosporine) * Diagnosed and active CNS disease or metastatic lesions * Major surgery within 4 weeks of starting the study * Pregnant or nursing * Uncontrolled disease (e.g., diabetes, hypertension, thyroid disease) * History of heart disease * History of any condition requiring treatment with anti-inflammatory, anti-platelet drugs or steroids * Diagnosed with HIV or hepatitis